Genetic Technologies (ASX:GTG)
Genetic Technologies (ASX:GTG) Limited offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
Latest Article
GTG Validates Cancer Tests As it Looks to Global Expansion
May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Related Genetic Technologies (ASX:GTG) articles
ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth
Apr 8, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
